SML1931

SLV320

≥98% (HPLC)

• Synonym(e): 4-[(4-trans-Hydroxycyclohexyl)amino]-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine, Derenofylline, SLV 320, SLV-320, trans-4-[(2-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexanol
• Empirische Formel (Hill-System): C₁₈H₂₀N₄O
• CAS-Nummer: 251945-92-3
• Molekulargewicht: 308.38
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: O[C@H]1CC[C@@H](CC1)NC2=NC(C3=CC=CC=C3)=NC4=C2C=CN4
• InChI: 1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)
• InChIKey: RBZNJGHIKXAKQE-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

SLV320 is an orally active, high-affinity adenosine receptor A1 antagonist (pKi = 9.0 against 3H-DPCPX for binding human A1R and 8.6 against 3H-CCPA for binding rat A1R) that exhibits higher A1R-selectivity than DPCPX over other adenosine receptor subtypes (Fold-selectivity/subtypes = 200/hA3, 398/hA2a, 3981/hA2b). SLV320 displays much reduced or little affinity toward a panel of 94 other receptors and no inhibitory activity against PDE1-6 (IC50 ≥1 μM). SLV320 selectively reduces A1R-mediated bradycardia (ED50 = 0.49 mg/kg via p.o. or 0.25 mg/kg via i.v. 10 min prior to 100 μg/kg adenosine i.v. challenge), but not A2R-dependent hypotension (up to 2 mg/kg) among adenosin-challenged rats. When administered via food intake, SLV320 efficacy is demonstrated in experimental models of chronic renal failure (CRF; 10 mg/kg/day) and liver cirrhosis (5.1 mg/kg/day p.o.) in rats in vivo.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable